deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT03399318

Aggressive Antipyretics for Fever Reduction in CNS Malaria

Aggressive Antipyretics in CNS Malaria: A Randomized-Controlled Trial Assessing Antipyretic Efficacy and Parasite Clearance Effects

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Conditions Coma Fever Hyperpyrexia Malaria Parasitemia Seizures
Interventions Acetaminophen Ibuprofen placebo for acetaminophen placebo for ibuprofen
Updated 17 times since 2018 Last updated: Feb 9, 2024 Started: Jan 7, 2019 Primary completion: Dec 2, 2022 Completion: Dec 2, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Coma and Fever and is currently completed. National Institute of Neurological Disorders and Stroke (NINDS) leads this study, which shows 17 recorded versions since 2019 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Apr 2019 · 8 months · monthly snapshot~Apr 2019 – ~Jul 2019 · 3 months · monthly snapshot~Jul 2019 – ~Nov 2019 · 4 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jul 2020 · 7 months · monthly snapshot~Jul 2020 – ~Nov 2020 · 4 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jul 2022 · 10 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Aug 2023 · 11 months · monthly snapshot~Aug 2023 – ~Apr 2024 · 8 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Apr 2024 — Jul 2024 [monthly]

    Completed PHASE2

  4. Aug 2023 — Apr 2024 [monthly]

    Completed PHASE2

  5. Sep 2022 — Aug 2023 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

▶ Show 12 earlier versions

  1. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  2. Sep 2021 — Jul 2022 [monthly]

    Recruiting PHASE2

  3. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  4. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  5. Jul 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  6. Dec 2019 — Jul 2020 [monthly]

    Recruiting PHASE2

  7. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  8. Jul 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  9. Apr 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

  10. Aug 2018 — Apr 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  11. Jun 2018 — Aug 2018 [monthly]

    Not Yet Recruiting PHASE2

  12. Feb 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Neurological Disorders and Stroke (NINDS)
  • University of Rochester
Data source: University of Rochester

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations